carbon monoxide has been researched along with Fibrosis in 21 studies
Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed)
carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to investigate the toxicity of carbon monoxide (CO) in rats with right ventricle (RV) remodeling induced by hypoxic pulmonary hypertension (PHT)." | 7.74 | Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension. ( Antier, D; Bonnet, P; Eder, V; Gautier, M; Hanton, G; Le Net, JL, 2007) |
| "Carbon monoxide (CO) is a critical endogenous signaling transducer with known anti-inflammatory and anti-fibrotic effects but its therapeutic potential in CLAD remains to be fully elucidated." | 5.91 | The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation. ( Aoki, Y; Combs, MP; Fitzgerald, L; Lama, VN; Lyu, D; McLinden, AP; Mimura, T; Misumi, K; Osterholzer, JJ; Pinsky, DJ; Vittal, R; Walker, NM, 2023) |
| " Previously we developed a nano micellar CO donor SMA/CORM2 which shows superior bioavailability and therapeutic potential in many inflammatory disease models." | 5.72 | Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathway. ( Cui, Y; Fang, J; Guo, C; Hu, W; Song, B; Xia, M; Xia, Z; Xu, D; Xue, Y; Zhang, C; Zhang, S, 2022) |
| "Tubulointerstitial fibrosis is a hallmark of chronic progressive kidney disease leading to end-stage renal failure." | 5.35 | Protective effects of low-dose carbon monoxide against renal fibrosis induced by unilateral ureteral obstruction. ( Choi, ME; He, Y; Kim, SI; Kwak, JH; Lee, JY; Wang, L, 2008) |
| "We aimed to investigate the toxicity of carbon monoxide (CO) in rats with right ventricle (RV) remodeling induced by hypoxic pulmonary hypertension (PHT)." | 3.74 | Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension. ( Antier, D; Bonnet, P; Eder, V; Gautier, M; Hanton, G; Le Net, JL, 2007) |
| " Fifty-eight patients with normal liver function, 14 patients with chronic hepatitis, 28 patients with hepatic cirrhosis, and 4 patients with obstructive jaundice were studied by positron-emission tomography scan after the single breath inhalation of 20 mCi of high specific activity 15O-labeled carbon monoxide." | 3.69 | Quantitative measurement of human tissue hepatic blood volume by C15O inhalation with positron-emission tomography. ( Koyama, H; Masuyama, M; Oguro, A; Takahashi, T; Taniguchi, H, 1996) |
| "Carbon monoxide (CO) is a critical endogenous signaling transducer with known anti-inflammatory and anti-fibrotic effects but its therapeutic potential in CLAD remains to be fully elucidated." | 1.91 | The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation. ( Aoki, Y; Combs, MP; Fitzgerald, L; Lama, VN; Lyu, D; McLinden, AP; Mimura, T; Misumi, K; Osterholzer, JJ; Pinsky, DJ; Vittal, R; Walker, NM, 2023) |
| " Previously we developed a nano micellar CO donor SMA/CORM2 which shows superior bioavailability and therapeutic potential in many inflammatory disease models." | 1.72 | Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathway. ( Cui, Y; Fang, J; Guo, C; Hu, W; Song, B; Xia, M; Xia, Z; Xu, D; Xue, Y; Zhang, C; Zhang, S, 2022) |
| " The secondary aim was to explore the applicability of standard CO dosing methodologies to this patient population." | 1.56 | Application of the optimized carbon monoxide rebreathing method for the measurement of total haemoglobin mass in chronic liver disease. ( Grocott, MPW; Kumar, SB; Montgomery, HE; Otto, JM; Plumb, JOM; Schmidt, W; Wright, M, 2020) |
| "Tubulointerstitial fibrosis is a hallmark of chronic progressive kidney disease leading to end-stage renal failure." | 1.35 | Protective effects of low-dose carbon monoxide against renal fibrosis induced by unilateral ureteral obstruction. ( Choi, ME; He, Y; Kim, SI; Kwak, JH; Lee, JY; Wang, L, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 6 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, Z | 1 |
| Zhang, C | 1 |
| Guo, C | 1 |
| Song, B | 1 |
| Hu, W | 1 |
| Cui, Y | 1 |
| Xue, Y | 1 |
| Xia, M | 1 |
| Xu, D | 1 |
| Zhang, S | 1 |
| Fang, J | 1 |
| Zhang, K | 1 |
| Zou, X | 1 |
| Ma, Z | 1 |
| Liu, X | 1 |
| Qiu, C | 1 |
| Xie, L | 1 |
| Lin, Z | 1 |
| Li, S | 1 |
| Wu, Y | 1 |
| Aoki, Y | 2 |
| Walker, NM | 2 |
| Misumi, K | 2 |
| Mimura, T | 2 |
| Vittal, R | 2 |
| McLinden, AP | 2 |
| Fitzgerald, L | 2 |
| Combs, MP | 2 |
| Lyu, D | 2 |
| Osterholzer, JJ | 2 |
| Pinsky, DJ | 2 |
| Lama, VN | 2 |
| Du, K | 1 |
| Zhu, Y | 1 |
| Mao, R | 1 |
| Qu, Y | 1 |
| Cui, B | 1 |
| Ma, Y | 1 |
| Zhang, X | 1 |
| Chen, Z | 1 |
| Nam, JG | 1 |
| Choi, Y | 1 |
| Lee, SM | 1 |
| Yoon, SH | 1 |
| Goo, JM | 1 |
| Kim, H | 1 |
| Plumb, JOM | 1 |
| Otto, JM | 1 |
| Kumar, SB | 1 |
| Wright, M | 1 |
| Schmidt, W | 1 |
| Grocott, MPW | 1 |
| Montgomery, HE | 1 |
| Laurence, J | 1 |
| Elhadad, S | 1 |
| Robison, T | 1 |
| Terry, H | 1 |
| Varshney, R | 1 |
| Woolington, S | 1 |
| Ghafoory, S | 1 |
| Choi, ME | 2 |
| Ahamed, J | 1 |
| Lin, S | 1 |
| Juriasingani, S | 1 |
| Sener, A | 1 |
| Öztürk, A | 1 |
| Kayacan, O | 1 |
| Chen, TL | 1 |
| Liao, JW | 1 |
| Chan, WH | 1 |
| Hsu, CY | 1 |
| Yang, JD | 1 |
| Ueng, TH | 1 |
| Shin, KM | 1 |
| Lee, KS | 1 |
| Chung, MP | 1 |
| Han, J | 1 |
| Bae, YA | 1 |
| Kim, TS | 1 |
| Chung, MJ | 1 |
| Nakao, A | 2 |
| Faleo, G | 1 |
| Nalesnik, MA | 2 |
| Seda-Neto, J | 1 |
| Kohmoto, J | 1 |
| Murase, N | 2 |
| Wang, G | 1 |
| Hamid, T | 1 |
| Keith, RJ | 1 |
| Zhou, G | 1 |
| Partridge, CR | 1 |
| Xiang, X | 1 |
| Kingery, JR | 1 |
| Lewis, RK | 1 |
| Li, Q | 1 |
| Rokosh, DG | 1 |
| Ford, R | 1 |
| Spinale, FG | 1 |
| Riggs, DW | 1 |
| Srivastava, S | 1 |
| Bhatnagar, A | 1 |
| Bolli, R | 1 |
| Prabhu, SD | 1 |
| Schmidt, SL | 1 |
| Nambiar, AM | 1 |
| Tayob, N | 1 |
| Sundaram, B | 1 |
| Han, MK | 1 |
| Gross, BH | 1 |
| Kazerooni, EA | 1 |
| Chughtai, AR | 1 |
| Lagstein, A | 1 |
| Myers, JL | 1 |
| Murray, S | 1 |
| Toews, GB | 1 |
| Martinez, FJ | 1 |
| Flaherty, KR | 1 |
| Knaapen, P | 1 |
| van Dockum, WG | 1 |
| Bondarenko, O | 1 |
| Kok, WE | 1 |
| Götte, MJ | 1 |
| Boellaard, R | 1 |
| Beek, AM | 1 |
| Visser, CA | 1 |
| van Rossum, AC | 1 |
| Lammertsma, AA | 1 |
| Visser, FC | 1 |
| Neto, JS | 1 |
| Toyokawa, H | 1 |
| Romanosky, AJ | 1 |
| Kimizuka, K | 1 |
| Kaizu, T | 1 |
| Hashimoto, N | 1 |
| Azhipa, O | 1 |
| Stolz, DB | 1 |
| Choi, AM | 1 |
| Tiev, KP | 1 |
| Cabane, J | 1 |
| Aubourg, F | 1 |
| Kettaneh, A | 1 |
| Ziani, M | 1 |
| Mouthon, L | 1 |
| Duong-Quy, S | 1 |
| Fajac, I | 1 |
| Guillevin, L | 1 |
| Dinh-Xuan, AT | 1 |
| Gautier, M | 1 |
| Antier, D | 1 |
| Bonnet, P | 1 |
| Le Net, JL | 1 |
| Hanton, G | 1 |
| Eder, V | 1 |
| Suliman, HB | 1 |
| Carraway, MS | 1 |
| Ali, AS | 1 |
| Reynolds, CM | 1 |
| Welty-Wolf, KE | 1 |
| Piantadosi, CA | 1 |
| Wang, L | 1 |
| Lee, JY | 1 |
| Kwak, JH | 1 |
| He, Y | 1 |
| Kim, SI | 1 |
| Taniguchi, H | 1 |
| Masuyama, M | 1 |
| Koyama, H | 1 |
| Oguro, A | 1 |
| Takahashi, T | 1 |
1 review available for carbon monoxide and Fibrosis
| Article | Year |
|---|---|
Is hydrogen sulfide a potential novel therapy to prevent renal damage during ureteral obstruction?
Topics: Animals; Carbon Monoxide; Disease Models, Animal; Fibrosis; Gasotransmitters; Humans; Hydrogen Sulfi | 2018 |
20 other studies available for carbon monoxide and Fibrosis
| Article | Year |
|---|---|
Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathway.
Topics: Animals; Anti-Inflammatory Agents; Carbon Monoxide; Cyclosporine; Fibrosis; Humans; Inflammasomes; M | 2022 |
Risk Factors Associated with Impairment in Pulmonary Diffusing Capacity among Patients with Noncystic Fibrosis Bronchiectasis.
Topics: Bronchiectasis; Carbon Monoxide; Fibrosis; Humans; Lung Diseases, Interstitial; Pulmonary Diffusing | 2022 |
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation.
Topics: Allografts; Animals; Bronchiolitis Obliterans; Carbon Monoxide; Collagen; Fibrosis; Graft Rejection; | 2023 |
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation.
Topics: Allografts; Animals; Bronchiolitis Obliterans; Carbon Monoxide; Collagen; Fibrosis; Graft Rejection; | 2023 |
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation.
Topics: Allografts; Animals; Bronchiolitis Obliterans; Carbon Monoxide; Collagen; Fibrosis; Graft Rejection; | 2023 |
The mitigating effect of exogenous carbon monoxide on chronic allograft rejection and fibrosis post-lung transplantation.
Topics: Allografts; Animals; Bronchiolitis Obliterans; Carbon Monoxide; Collagen; Fibrosis; Graft Rejection; | 2023 |
Medium-long term prognosis prediction for idiopathic pulmonary fibrosis patients based on quantitative analysis of fibrotic lung volume.
Topics: Carbon Monoxide; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Prognosis; Retrospective Stu | 2022 |
Prognostic value of deep learning-based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis.
Topics: Aged; Carbon Monoxide; Deep Learning; Fibrosis; Humans; Idiopathic Pulmonary Fibrosis; Lung; Male; P | 2023 |
Application of the optimized carbon monoxide rebreathing method for the measurement of total haemoglobin mass in chronic liver disease.
Topics: Carbon Monoxide; Carboxyhemoglobin; Female; Fibrosis; Hemoglobins; Humans; Liver Diseases; Male; Mid | 2020 |
HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-β1 and can be suppressed by exogenous carbon monoxide.
Topics: Animals; Blood Platelets; Carbon Monoxide; Cardiac Output; Echocardiography; Fibrosis; Heart Disease | 2017 |
Rising stars of DPLD survival: FVC and exercise desaturation (a single-center study)
Topics: Age Factors; Aged; Blood Pressure; Carbon Monoxide; Connective Tissue Diseases; Exercise; Exercise T | 2018 |
Induction of cardiac fibrosis and transforming growth factor-β1 by motorcycle exhaust in rats.
Topics: 7-Alkoxycoumarin O-Dealkylase; Air Pollutants; Animals; Atrial Natriuretic Factor; Carbon Monoxide; | 2013 |
Prognostic determinants among clinical, thin-section CT, and histopathologic findings for fibrotic idiopathic interstitial pneumonias: tertiary hospital study.
Topics: Bronchoalveolar Lavage Fluid; Carbon Monoxide; Female; Fibrosis; Humans; Lung Diseases, Interstitial | 2008 |
Low-dose carbon monoxide inhibits progressive chronic allograft nephropathy and restores renal allograft function.
Topics: Animals; Atrophy; Carbon Monoxide; Chronic Disease; Disease Models, Animal; Disease Progression; Dos | 2009 |
Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart.
Topics: Animals; Apoptosis; Carbon Monoxide; Cardiotonic Agents; Chronic Disease; Fibrosis; Gene Expression; | 2010 |
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.
Topics: Aged; Carbon Monoxide; Diffusion; Emphysema; Female; Fibrosis; Forced Expiratory Volume; Humans; Idi | 2011 |
Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET.
Topics: Adult; Aged; Carbon Monoxide; Cardiomyopathy, Hypertrophic; Case-Control Studies; Chronic Disease; F | 2005 |
Low-dose carbon monoxide inhalation prevents development of chronic allograft nephropathy.
Topics: Administration, Inhalation; Animals; Carbon Monoxide; Cell Adhesion Molecules; Cytokines; Fibrosis; | 2006 |
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide.
Topics: Aged; Carbon Monoxide; Echocardiography; Female; Fibrosis; Humans; Lung Diseases; Lung Diseases, Int | 2007 |
Continuous inhalation of carbon monoxide induces right ventricle ischemia and dysfunction in rats with hypoxic pulmonary hypertension.
Topics: Administration, Inhalation; Animals; Blood Flow Velocity; Blood Pressure; Carbon Monoxide; Carboxyhe | 2007 |
The CO/HO system reverses inhibition of mitochondrial biogenesis and prevents murine doxorubicin cardiomyopathy.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antibiotics, Antineoplastic; Antimetabolites; | 2007 |
Protective effects of low-dose carbon monoxide against renal fibrosis induced by unilateral ureteral obstruction.
Topics: Actins; Administration, Inhalation; Animals; Antimetabolites; Carbon Monoxide; Collagen Type I; Epit | 2008 |
Quantitative measurement of human tissue hepatic blood volume by C15O inhalation with positron-emission tomography.
Topics: Blood Volume; Carbon Monoxide; Coloring Agents; Female; Fibrosis; Hepatitis; Humans; Indocyanine Gre | 1996 |